BofA cuts Merit Medical stock price target on deal dilution

BofA Securities cut Merit Medical Systems' price target to $80 from $100 while keeping a Neutral rating, even as the company posted a strong Q1 with revenue of $382 million and EPS of $0.94, both ahead of expectations. Operating margin of 19.7% beat Street estimates by 180bps, and full-year revenue guidance was nudged up to $1.612 billion-$1.634 billion despite about 5 cents of dilution from the View Point deal. The mixed setup is supported by solid execution and guidance, but tempered by the reduced analyst target and the stock's 22.65% YTD decline.

Analysis

The key signal is not the quarter itself but the quality of the raise: management absorbed acquisition dilution while still nudging revenue higher, which suggests underlying demand is outpacing the incremental drag from integration. That matters because healthcare distributors and device peers tend to re-rate on margin durability, not headline growth; a 180bp operating margin beat is more powerful than a small revenue beat because it implies pricing and mix are holding even before any synergies are fully visible.

The market appears to be pricing MMSI as if the first-quarter outperformance is a one-off and the guidance math is conservative. That creates a setup where the next two catalysts can matter disproportionately: second-quarter guidance review and any evidence that the acquired asset is accretive faster than modeled. If management merely maintains the current run-rate, the stock can re-rate on multiple expansion alone, because the shares are already trading near technical lows despite fundamentals that are inflecting better than expected.

The second-order issue is competitive pressure on smaller medtech peers: if Merit can grow mid-single digits and expand margin while integrating M&A, competitors with weaker execution will face tougher investor comparisons and potentially higher cost of capital. The contrarian risk is that the current guidance framework may still be too cautious, limiting near-term upside until the company proves that the raised revenue range is not just offsetting dilution. In other words, this is a months-long rerating story rather than a days-long momentum trade, with downside mainly if integration slippage or reimbursement noise appears before the Q2 update.

Key Decisions for Investors

• Go long MMSI on weakness near the lows; target a 3-6 month mean reversion trade with roughly 15-20% upside if the market re-prices the margin beat and guidance floor.
• Pair trade: long MMSI / short a slower-growing medtech peer basket over the next 1-2 quarters; the relative setup favors names with proven margin expansion and M&A absorption versus those still relying on multiple defense.
• Buy MMSI call spreads 3-4 months out to express upside into the next guidance review while limiting premium outlay; best if implied volatility remains subdued after the earnings reset.
• Tight risk control: if the company does not raise Q2 commentary or book-to-bill rhetoric in the next update, trim 30-50% of the position, since the rerating thesis depends on follow-through rather than one quarter alone.